Woodward Diversified Capital LLC Purchases Shares of 2,856 Gilead Sciences, Inc. $GILD

Woodward Diversified Capital LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 2,856 shares of the biopharmaceutical company’s stock, valued at approximately $317,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Ariel Investments LLC boosted its position in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after acquiring an additional 30,630 shares during the period. Golden State Wealth Management LLC boosted its position in shares of Gilead Sciences by 14.5% in the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 109 shares during the period. One Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 34.8% in the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after acquiring an additional 2,364 shares during the period. Swedbank AB boosted its position in shares of Gilead Sciences by 0.8% in the first quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company’s stock valued at $237,393,000 after acquiring an additional 16,663 shares during the period. Finally, Covea Finance boosted its position in shares of Gilead Sciences by 69.5% in the second quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock valued at $5,732,000 after acquiring an additional 21,200 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the sale, the chief executive officer directly owned 605,725 shares of the company’s stock, valued at $69,016,306.50. This trade represents a 1.62% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock valued at $9,402,130 over the last three months. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 0.1%

GILD stock opened at $111.15 on Thursday. The business’s 50 day simple moving average is $114.47 and its 200 day simple moving average is $109.92. The firm has a market capitalization of $137.92 billion, a PE ratio of 22.14, a PEG ratio of 0.75 and a beta of 0.34. Gilead Sciences, Inc. has a 1-year low of $83.10 and a 1-year high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on GILD shares. UBS Group increased their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Finally, Rothschild & Co Redburn raised their target price on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.